BioCryst's Orladeyo Application Under Review In Israel For Hereditary Angioedema

The Israeli Ministry of Health has accepted for review BioCryst Pharmaceuticals Inc's BCRX application for Orladeyo to prevent recurrent attacks in patients with hereditary angioedema (HAE) 12 years and older.
The Israeli Ministry of Health also has granted an accelerated review.
In addition, BioCryst has entered into a distribution and supply agreement granting Neopharm Ltd to commercialize Orladeyo in Israel.
Price Action: BCRX shares are up 1.6% at $15.86 during the premarket session on the last check Wednesday.